Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Sarah Anderson [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 2, 2026, Sarah Anderson, Executive Vice President of Pharmacy, adopted a Rule 10b5-1 trading arrangement for the sale of up to 30,000 shares of our common stock, subject to certain conditions. The arrangement’s expiration date is May 31, 2027.
|
| Name | Sarah Anderson |
| Title | Executive Vice President |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 2, 2026 |
| Expiration Date | May 31, 2027 |
| Arrangement Duration | 455 days |
| Aggregate Available | 30,000 |
| Denise Devine [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On February 17, 2026, Denise Devine, a member of the Company’s Board of Directors, adopted a Rule 10b5-1 trading arrangement for the sale of up to 4,000 shares of our common stock, subject to certain conditions. The arrangement’s expiration date is February 12, 2027.
|
| Name | Denise Devine |
| Title | Board of Directors |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | February 17, 2026 |
| Expiration Date | February 12, 2027 |
| Arrangement Duration | 360 days |
| Aggregate Available | 4,000 |